Boostani Farnaz, Dolatkhah Roya, Fakhrjou Ashraf, Farassati Faris, Sanaat Zohreh
Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Tabriz University of Medical Sciences, Tabriz, Iran.
Onco Targets Ther. 2018 Jan 19;11:449-457. doi: 10.2147/OTT.S149210. eCollection 2018.
Recently, it was found that the overexpression and mutation status of affect cancer progression and patient outcome in several human tumors. We aimed to evaluate the clinicopathologic significance of in patients with breast cancer.
This was an analytical descriptive study of surgical specimens of primary breast tumors. Specimens were analyzed immunohistochemically for , estrogen receptor, progesterone receptor, Ki-67, P53, and human epidermal growth factor receptor 2 (HER2) expressions. Regression analysis was performed to calculate hazard ratios (HRs) and 95% CIs. Kaplan-Meier and Cox regression models were used to estimate the overall survival (OS) and disease-free survival (DFS).
We included 100 patients with breast cancer (mean age 51.05±9.54 years). The multivariate regression analysis showed that HER2-positive patients had approximately twice the levels of expression compared with HER2-negative patients (HR 2.16, 95% CI 0.48-11.49). The likelihood of expression was significantly higher in patients with lymph node involvement than in those without (HR 8.44, 95% CI 3.06-23.33; ≤0.05). expression did not have any significant effect on the OS, although the mean OS in high expression was shorter than for those with low expression (655 vs 787 days; log-rank =0.336). The mean DFS was 487 days for patients with high expression compared with 908 days for those with low expression (log-rank =0.188).
There was no association found between expression and OS and DFS in our patients. Further studies involving larger sample sizes, and conducted in different populations, are needed to validate this hypothesis.
最近发现，[具体基因名称未给出]的过表达和突变状态在几种人类肿瘤中影响癌症进展和患者预后。我们旨在评估[具体基因名称未给出]在乳腺癌患者中的临床病理意义。
这是一项对原发性乳腺肿瘤手术标本的分析性描述性研究。对标本进行免疫组织化学分析，检测[具体基因名称未给出]、雌激素受体、孕激素受体、Ki-67、P53和人表皮生长因子受体2（HER2）的表达。进行回归分析以计算风险比（HRs）和95%置信区间（CIs）。使用Kaplan-Meier和Cox回归模型估计总生存期（OS）和无病生存期（DFS）。
我们纳入了100例乳腺癌患者（平均年龄51.05±9.54岁）。多因素回归分析显示，HER2阳性患者的[具体基因名称未给出]表达水平约为HER2阴性患者的两倍（HR 2.16，95% CI 0.48 - 11.49）。有淋巴结转移的患者[具体基因名称未给出]表达的可能性显著高于无淋巴结转移的患者（HR 8.44，95% CI 3.06 - 23.33；P≤0.05）。[具体基因名称未给出]表达对总生存期没有显著影响，尽管高[具体基因名称未给出]表达患者的平均总生存期短于低[具体基因名称未给出]表达患者（655天对787天；对数秩检验=0.336）。高[具体基因名称未给出]表达患者的平均无病生存期为487天，而低[具体基因名称未给出]表达患者为908天（对数秩检验=0.188）。
在我们的患者中，未发现[具体基因名称未给出]表达与总生存期和无病生存期之间存在关联。需要进一步开展涉及更大样本量且在不同人群中进行的研究来验证这一假设。
